University of Erlangen–Nuremberg

Countdown to the Finals of the ASC24 Student Supercomputer Challenge!

Retrieved on: 
Tuesday, April 2, 2024
Research, Apps, Applications, Technology, Oil, Gas, Software, Energy, Hardware, University, Science, Education, Peking University, Shanghai Jiao Tong University, Algorithm, Southwest Petroleum University, Shanghai University, Overalls, Student, LLM, Huachung University, ASC, Water, University of Erlangen–Nuremberg, Lanzhou University, Chinese, National university

The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.

Key Points: 
  • The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.
  • Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students.
  • Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them.
  • The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.

ASC24 Student Supercomputer Challenge: Twenty-five University Teams Worldwide Advance to the Finals

Retrieved on: 
Wednesday, February 7, 2024
Research, Technology, Engineering, Software, Manufacturing, Hardware, University, Data Management, Science, Education, Memory, Southwest Petroleum University, Shanghai University, CPU, Peking University, National university, Chinese, Shanghai Jiao Tong University, National Tsing Hua University, National University of Córdoba, University of Erlangen–Nuremberg, LLM, ASC, Water, Data, Qinghai University, Huachung University, Algorithm, Risk management

Over 300 universities worldwide participated, with twenty-five standout teams advancing to the finals.

Key Points: 
  • Over 300 universities worldwide participated, with twenty-five standout teams advancing to the finals.
  • Among the finalists are renowned institutions such as Huazhong University of Science and Technology, Peking University, the Chinese University of Hong Kong, National Tsing Hua University, Friedrich-Alexander-University Erlangen-Nuremberg, and the National University of Cordoba.
  • The ASC24 finals feature a lineup of traditional powerhouses, including Peking University - the champion of the 10th ASC onsite finals; the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals; University of Science and Technology of China; Shanghai Jiao Tong University; and Friedrich-Alexander-University Erlangen-Nuremberg.
  • Additionally, there is great excitement surrounding the debut of teams from National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, marking their first appearance in the ASC finals this year.

German Design Furniture Retailer Cairo Teams Up with ARHT to Revolutionize its Customer Experience with Holographic Sales Assistants

Retrieved on: 
Tuesday, January 16, 2024
CAPSULE, Fraunhofer, Research, NRF, Fraunhofer Society, Partnership, IIS, German, OTCQB, University of Erlangen–Nuremberg, Integrated circuit, ART

Leveraging ARHT hologram technology, Cairo plans to "duplicate" their sales assistants as live holograms and beam them via ARHT CAPSULE to other retail shops, offering a unique and immersive shopping experience for their customers.

Key Points: 
  • Leveraging ARHT hologram technology, Cairo plans to "duplicate" their sales assistants as live holograms and beam them via ARHT CAPSULE to other retail shops, offering a unique and immersive shopping experience for their customers.
  • "I saw the potential of holograms during my visit to the NRF Big Show last year," confesses Furchheim.
  • If successful, Cairo aims to open smaller stores in various locations, offering customers the chance to interact with holographic sales assistants.
  • With the holographic sales assistant, Cairo aims to reshape the way customers interact with their products and bring a new level of personalization to the retail experience.

Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”

Retrieved on: 
Tuesday, November 7, 2023
Kidney, Chronic kidney disease, EST, Senior, CKD, University of Michigan, Fibrinolysis, University of Erlangen–Nuremberg, University, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical-stage company focused on transforming the treatment of kidney diseases, today announced that management will host a virtual event titled, “Transforming the Treatment Landscape of Chronic Kidney Disease,” (CKD) on November 14, 2023 from 11:00 a.m. to 12:30 p.m. EST.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical-stage company focused on transforming the treatment of kidney diseases, today announced that management will host a virtual event titled, “Transforming the Treatment Landscape of Chronic Kidney Disease,” (CKD) on November 14, 2023 from 11:00 a.m. to 12:30 p.m. EST.
  • The program will include remarks from executive and scientific management relating to Walden’s clinical and preclinical programs, where they are pursuing disease-modifying treatments for kidney diseases.
  • (University of Michigan, Kidney Health Initiative) and Mario Schiffer, M.D.
  • (Friedrich-Alexander-University Erlagen-Nürnberg) to discuss the CKD treatment landscape and the great need for better therapeutic options for this patient population.

Cipher Neutron and the Canadian University of Alberta Enter into Collaboration Discussions on Advanced Research in AEM Electrolyser Membrane Catalysts

Retrieved on: 
Wednesday, July 26, 2023
Neutron, Hydrogen, Membrane, University of Alberta, PGM, AEM, University of Siegen, University, Engineering, University of Erlangen–Nuremberg, Electrolysed water, Research, Assistant, Government, Science, Public expenditure, CAPEX, Green hydrogen, Catalysis, Materials science, Scripps Energy & Materials Center, OPEX, Collaboration, International Society, Oil

Toronto, Ontario--(Newsfile Corp. - July 26, 2023) - Cipher Neutron Inc. ("Cipher Neutron", "CN" or the "Company") and the University of Alberta ("University of Alberta") in Canada are pleased to jointly announce that they have entered into discussions to collaborate on advanced research in AEM Electrolyser Membrane Catalysts (the "Collaboration").

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 26, 2023) - Cipher Neutron Inc. ("Cipher Neutron", "CN" or the "Company") and the University of Alberta ("University of Alberta") in Canada are pleased to jointly announce that they have entered into discussions to collaborate on advanced research in AEM Electrolyser Membrane Catalysts (the "Collaboration").
  • The Collaboration provides for the development of specialized Membrane Catalysts which can be used in the AEM Green Hydrogen Electrolysers of Cipher Neutron to further increase the superior efficiencies of Green Hydrogen production achieved by Cipher Neutron.
  • The Research by the University of Alberta is expected to be endorsed in part by MITACS and Cipher Neutron, and the University of Alberta intends to continue with this prestigious MITACS sponsorship.
  • Gurjant Randhawa, President and CEO of Cipher Neutron, stated, "Cipher Neutron welcomes the collaboration with Dr. Shiva Mohajernia and the University of Alberta on its ongoing Membrane Catalyst projects.

Fresenius Medical Care appoints Martin Fischer as Chief Financial Officer

Retrieved on: 
Monday, July 10, 2023
Attention, Informatics, Fresenius Medical Care, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Frankfurt Stock Exchange, COVID-19, Disclosure, Supervisory board, MBA, Columbia Business School, Limited partnership, Organization, Dialysis, Siemens Healthineers, Patient, Kidney, Siemens, University of Erlangen–Nuremberg, Applied science, ARE, FMS, Reutlingen University, FME, Pharmaceutical industry, Management

WALTHAM, Mass., July 10, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer as of October 1, 2023. He will succeed Helen Giza who was appointed as Chief Executive Officer and Chair of the Management Board in December 2022 and continues to serve as acting Chief Financial Officer, until her successor will join. Martin Fischer will be based in Bad Homburg, Germany and will assume responsibility for the Global Finance Organization of Fresenius Medical Care. Upon effectiveness of the Company's proposed change of form from KGaA to German stock corporation, Martin Fischer will become a member of the Management Board of Fresenius Medical Care AG.

Key Points: 
  • WALTHAM, Mass., July 10, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer as of October 1, 2023.
  • Martin Fischer will be based in Bad Homburg, Germany and will assume responsibility for the Global Finance Organization of Fresenius Medical Care.
  • Upon effectiveness of the Company's proposed change of form from KGaA to German stock corporation, Martin Fischer will become a member of the Management Board of Fresenius Medical Care AG.
  • Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, says: "With Martin Fischer's appointment, we are strengthening a vital function in the Management Board of Fresenius Medical Care.

AlgoTx Progresses ATX01 in Two Indications

Retrieved on: 
Thursday, March 30, 2023
Biotechnology, FDA, Health, Clinical Trials, Oncology, ACT, Exercise, Erythromelalgia, Mayo Clinic, EU, Spinal cord, University of Erlangen–Nuremberg, Skin, Hope, Brain, CIPN, EMA, Pain, Nav1.7, Patient, Swelling, EASE, Clinical professor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Red, Food, Nav1.8, Peripheral nervous system, Pharmaceutical industry

Meanwhile, the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Key Points: 
  • Meanwhile, the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN).
  • Both programs have been granted Fast Track Designation by the FDA.
  • AlgoTx is conducting the ACT study as part of its US / EU Phase 2 program in the indication of CIPN.
  • AlgoTx has obtained an Orphan Disease Designation from both FDA and EMA to support development of ATX01 in this indication.

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

Retrieved on: 
Monday, September 19, 2022
Wolf Prize, Bioinformatics, Therapy, Safety, Molecular biology, Melanoma, MD, RNA transfection, Center, Faculty of Pharmacy, University of Lisbon, University, University of Erlangen–Nuremberg, Hebrew language, HCRI, Biochemistry, Hadassah Medical Center, Immunotherapy, Neoplasm, Cancer, Physician, Cancer epigenetics, Free University of Brussels (1834–1969), Goal, Biocomputing, Acute myeloid leukemia, Uveal melanoma, Centre for Genomic Regulation, Bar-Ilan University, RNA, Research, RNA splicing, Immune system, Pharmaceutical industry, Vaccine, Dietary supplement, Merck, Biobank

JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Key Points: 
  • JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.
  • While RNA-based therapies, namely mRNA vaccines, shined during the pandemic and saved millions of lives, they have yet to be successfully tested in cancer therapies.
  • About the Hadassah Cancer Research Institute:
    Hadassah Cancer Research Institute (HCRI) is a translational research arm of Hadassah Medical Organization and Sharett Cancer Center in Jerusalem.
  • For additional information on the Hadassah Cancer Research Institute and CanceRNA, contact:

DGAP-News: DEUTZ AG: DEUTZ appoints Dr. Petra Mayer to the Board of Management

Retrieved on: 
Tuesday, August 23, 2022
DGAP, COO, University, Technology, Continental, Management, Hand, Engineering, EBIT, News, Solution, Friedrich, Lifting, Board, ZF Friedrichshafen, Board of directors, Supervisory board, Senior, ZF, Siva Power, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, University of Erlangen–Nuremberg, Industry, Security (finance), Autoliv

Dr. Petra Mayer to join the Board of Management as COO on November 1, 2022

Key Points: 
  • Dr. Petra Mayer to join the Board of Management as COO on November 1, 2022
    The Supervisory Board of DEUTZ AG is continuing its restructuring of the Board of Management.
  • Dr. Petra Mayer will be joining the Board of Management on November 1, 2022.
  • Dietmar Voggenreiter, Chairman of the Supervisory Board at DEUTZ AG: The reorganisation of the Board of Management is progressing well.
  • Dr. Sebastian C. Schulte, Chief Executive Officer of DEUTZ AG: I am very much looking forward to working with Petra Mayer on the Board of Management.

Neoss® Group welcomes Dr. Sebastian Bauer as Director Product Management

Retrieved on: 
Thursday, July 28, 2022
Goal, University, Glass, Materials science, CEO, Master, Research, Solution, Nobel Biocare, Catalysis, University of Erlangen–Nuremberg, Ceramic, Patient, Osseointegration, ENSCM, Growth, Science, Laboratoires Expanscience, Management

ZURICH, July 28, 2022 /PRNewswire/ -- Neoss Group is happy to welcome Dr. Sebastian Bauer to our growing team as our Director Product Management as of July 1st, 2022.

Key Points: 
  • ZURICH, July 28, 2022 /PRNewswire/ -- Neoss Group is happy to welcome Dr. Sebastian Bauer to our growing team as our Director Product Management as of July 1st, 2022.
  • Sebastian will lead the global product management team and the product strategy and product portfolio management.
  • As Director Product Management, Sebastian will have responsibility for the product portfolio's success as well as manage all key stakeholders related to the product line to achieve the vision and goals for the product portfolio in the future.
  • "Sebastian will be a very important part of the future of our organization, and I am happy to welcome him to Neoss as our Director Product Management.